Biomarker: PAI-1

Histology type: endometrial carcinoma

Country: USA

Region: Kentucky

Study type: retrospective study

Followed up time :

Conclusion: Multivariate analysis revealed that PAI-1 was a predictor of survival although stage was the strongest independent factor.

Sample type : tissue

Sample method: ELISAs

Expression pattern : elevate

Statictics: Mean (SD);Range

Cohort age: 64.5;31–92

Funtion Uniprot: Serine protease inhibitor. Inhibits TMPRSS7 (PubMed:15853774). Is a primary inhibitor of tissue-type plasminogen activator (PLAT) and urokinase-type plasminogen activator (PLAU). As PLAT inhibitor, it is required for fibrinolysis down-regulation and is responsible for the controlled degradation of blood clots (PubMed:8481516, PubMed:9207454, PubMed:17912461). As PLAU inhibitor, it is involved in the regulation of cell adhesion and spreading (PubMed:9175705). Acts as a regulator of cell migration, independently of its role as protease inhibitor (PubMed:15001579, PubMed:9168821). It is required for stimulation of keratinocyte migration during cutaneous injury repair (PubMed:18386027). It is involved in cellular and replicative senescence (PubMed:16862142). Plays a role in alveolar type 2 cells senescence in the lung (By similarity). Is involved in the regulation of cementogenic differentiation of periodontal ligament stem cells, and regulates odontoblast differentiation and dentin formation during odontogenesis (PubMed:25808697, PubMed:27046084)

UniProt ID: P05121

UniProt Link: https://www.uniprot.org/uniprotkb/P05121/entry

Molecular function from UniProt:

Tissue specificity from UniProt: Expressed in endothelial cells (PubMed:2430793, PubMed:3097076). Found in plasma, platelets, and hepatoma and fibrosarcoma cells

Subcellular UniProt: #Secreted

Alternative name from UniProt:

Recommended name: Plasminogen activator inhibitor 1

Gene name from HGNC: SERPINE1 (PAI, PAI1, PLANH1)

HPA class: Cancer-related genes Candidate cardiovascular disease genes Disease related genes FDA approved drug targets Human disease related genes Plasma proteins

AlphaFold DB: P05121

AlphaFold Link: https://alphafold.ebi.ac.uk/entry/P05121

HPA link: https://www.proteinatlas.org/ENSG00000106366-SERPINE1

Tissue specificity RNA from HPA: Tissue enhanced (placenta)

Tissue expression from HPA: Expressed in several tissues, mainly in placenta. Positivity in plasma.

Single cell type specificity Cell type enhanced (Syncytiotrophoblasts, Smooth muscle cells, Pancreatic endocrine cells, Endothelial cells, Fibroblasts)

Immune cell specificity: Immune cell enriched (NK-cell)

Subcellular summary HPA Located in Cytosol (Single cell variability)

Cancer prognostic summary HPA Prognostic marker in renal cancer (unfavorable), stomach cancer (unfavorable), lung cancer (unfavorable), head and neck cancer (unfavorable), colorectal cancer (unfavorable), cervical cancer (unfavorable) and urothelial cancer (unfavorable)

Pathology link: https://www.proteinatlas.org/ENSG00000106366-SERPINE1/pathology

Pathology endo: https://www.proteinatlas.org/ENSG00000106366-SERPINE1/pathology/endometrial+cancer

Phenotype ID: 613329

Disease: Plasminogen activator inhibitor-1 deficiency (PAI-1D)

Note1: The disease is caused by variants affecting the gene represented in this entry. A rare PAI-1D mutation resulting in a frameshift and protein truncation has been found in an Old Order Amish community. Homozygous mutation carriers suffer from episodes of major hemorrhage, while heterozygous carriers do not manifest abnormal bleeding (PubMed:9207454). Heterozygosity for the mutation is associated with longer leukocyte telomere length, lower fasting insulin levels, lower prevalence of diabetes mellitus, and a longer life span (PubMed:29152572)

OMIM: 173360

OMIM link1: https://www.omim.org/entry/613329

OMIM link2: https://www.omim.org/entry/173360

HGNC ID: HGNC:8583

HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8583